1-3 of 3
Lixin Jiang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Elias Jabbour, Hagop M. Kantarjian, Paul B. Koller, Omer Jamy, Vivian G. Oehler, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Jorge Cortes, Huanshan Guo, Zi Chen, Lei Fu, Hengbang Wang, Lixin Jiang, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1798.
https://doi.org/10.1182/blood-2023-187744
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Elias Jabbour, Paul B. Koller, Vivian G. Oehler, Omer H Jamy, Sudipto Mukherjee, Anthony M. Hunter, Maria R. Baer, Joseph T. Beck, Zi Chen, Huanshan Guo, Lei Fu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian, Lixin Jiang, Cunlin Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 200–202.
https://doi.org/10.1182/blood-2022-162387
Published: 2022
Journal Articles

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Elias J. Jabbour, Hagop Kantarjian, Ghayas C. Issa, Joseph Thaddeus Beck, Rebecca B. Klisovic, Sudipto Mukherjee, Vivian G. Oehler, Zi Chen, Ming Lu, Tommy Fu, Lixin Jiang, Yifan Zhai, Dajun Yang
Journal: Blood
Blood (2021) 138 (Supplement 1): 2551.
https://doi.org/10.1182/blood-2021-152693
Published: 2021